REGNRegeneron PharmaceuticalsFinished
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Carcinoma，Non-Small-Cell Lung · Lung Carcinomas, Non-Small-Cell · Non-small-cell Lung Carcinoma · Nonsmall Cell Lung Cancer
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 712 (final count)
- Started
- May 29, 2017
- Main results expected
- Apr 18, 2025
- Fully finished
- Apr 18, 2025
- Results posted
- Jun 25, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to 94 months
Progression-free Survival (PFS) Per Blinded IRC
Measured over: Up to 94 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03088540 · record last updated 2026-06-25 · checked 2026-11-09 15:47 UTC